|
Back to Home » December 2020 News » Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia |
Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia |
December 06, 2020
RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus...
Source URL: http://prnmedia.prnewswire.com/news-releases/disease-free-survival-data-from-captivate-study-demonstrate-benefit-of-imbruvica-ibrutinib-based-regimen-as-fixed-duration-first-line-treatment-for-patients-with-chronic-lymphocytic-leukemia-301186838.html
|
|
|
|
